Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 4/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12706204 | 0.83 | KDM4E (0.41) | KDM4EPIK3CD | |
| SCHEMBL149338 | 0.79 | — | — | |
| SCHEMBL16044897 | 0.79 | — | — | |
| SCHEMBL11486224 | 0.76 | KDM4E (0.36) | KDM4EPIK3CD | |
| SCHEMBL12129103 | 0.69 | KDM4E (0.37) | KDM4EPIK3CD | |
| SCHEMBL1031882 | 0.69 | — | — | |
| SCHEMBL4337347 | 0.69 | HSD11B1 (0.36) | KDM4E | |
| Acrylic Acid SCHEMBL9444086 | 0.68 | KDM4E (0.43) | KDM4EPIK3CD | |
| SCHEMBL12641147 | 0.68 | KDM4E (0.39) | KDM4EPIK3CD | |
| SCHEMBL1717112 | 0.67 | PIK3CD (0.53) | KDM4EPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022023229-A1 | CURABLE COMPOSITIONS AND PRODUCTS FORMED THEREFROM, AND METHODS OF FORMING THE SAME | COVESTRO DEUTSCHLAND AG (DE) | 2022-02-03 | — | — | WO | claimed |
| EP-3945101-A1 | CURABLE COMPOSITIONS AND PRODUCTS FORMED THEREFROM, AND METHODS OF FORMING THE SAME | Covestro Deutschland AG (DE) | 2022-02-02 | — | — | EP | claimed |
| EP-3921312-A1 | CURABLE COMPOSITIONS, PRODUCTS AND ARTICLES FORMED THEREFROM, AND METHODS OF FORMING THE SAME | Covestro LLC (US) | 2021-12-15 | — | — | EP | claimed |
| EP-3218423-B1 | COMB POLYURETHANE DISPERSANTS | HUNTSMAN PETROCHEMICAL LLC (US) | 2021-01-06 | — | — | EP | claimed |
| US-10793667-B2 | Curable compositions, products and articles formed therefrom, and methods of forming the same | COVESTRO DEUTSCHLAND AG (DE) | 2020-10-06 | — | — | US | claimed |
| US-20200255585-A1 | CURABLE COMPOSITIONS, PRODUCTS AND ARTICLES FORMED THEREFROM, AND METHODS OF FORMING THE SAME | COVESTRO LLC | 2020-08-13 | — | — | US | claimed |
| WO-2020163464-A1 | CURABLE COMPOSITIONS, PRODUCTS AND ARTICLES FORMED THEREFROM, AND METHODS OF FORMING THE SAME | COVESTRO LLC (US) | 2020-08-13 | — | — | WO | claimed |
| EP-3218423-A1 | COMB POLYURETHANE DISPERSANTS | Huntsman Petrochemical LLC (US) | 2017-09-20 | — | — | EP | claimed |
| US-20170240756-A1 | COMB POLYURETHANE DISPERSANTS | HUNTSMAN PETROCHEMICAL LLC | 2017-08-24 | — | — | US | claimed |
| WO-2016077147-A1 | COMB POLYURETHANE DISPERSANTS | HUNTSMAN PETROCHEMICAL LLC (US) | 2016-05-19 | — | — | WO | claimed |
| US-7183360-B2 | Method for crosslinking hydrogels with morpholine-2,3-diones | BASF AKTIENGESELLSCHAFT (DE) | 2007-02-27 | — | — | US | claimed |
| EP-1436335-B1 | METHOD FOR CROSSLINKING HYDROGELS WITH MORPHOLINE-2,3-DIONES | BASF AG (DE) | 2005-01-26 | — | — | EP | claimed |
| US-20040231065-A1 | Method for crosslinking hydrogels with morpholine-2,3-diones | BASF AKTIENGESELLSCHAFT, A GERMAN CORPORATION (DE) | 2004-11-25 | — | — | US | claimed |
| EP-1436335-A1 | METHOD FOR CROSSLINKING HYDROGELS WITH MORPHOLINE-2,3-DIONES | BASF AKTIENGESELLSCHAFT (DE) | 2004-07-14 | — | — | EP | claimed |
| WO-2003031482-A1 | METHOD FOR CROSSLINKING HYDROGELS WITH MORPHOLINE-2,3-DIONES | BASF AKTIENGESELLSCHAFT (DE) | 2003-04-17 | — | — | WO | claimed |
| WO-2022023229-A1 | CURABLE COMPOSITIONS AND PRODUCTS FORMED THEREFROM, AND METHODS OF FORMING THE SAME | COVESTRO DEUTSCHLAND AG (DE) | 2022-02-03 | — | — | WO | disclosed |
| EP-3945101-A1 | CURABLE COMPOSITIONS AND PRODUCTS FORMED THEREFROM, AND METHODS OF FORMING THE SAME | Covestro Deutschland AG (DE) | 2022-02-02 | — | — | EP | disclosed |
| EP-0371640-A1 | A compound containing an oxamic acid group, a process for producing the compound, and a resin composition containing the compound | NIPPON PAINT CO., LTD. (JP) | 1990-06-06 | — | — | EP | disclosed |
| US-4184024-A | Polyurethanes prepared from polyols from 2,3-morpholinediones | TEXACO DEVELOPMENT CORP. (US) | 1980-01-15 | — | — | US | disclosed |
| US-4118422-A | Polyols from 2,3-morpholinediones | TEXACO DEVELOPMENT CORP. (US) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040231065-A1 | Method for crosslinking hydrogels with morpholine-2,3-diones | ADM2, COL1A1, MDN1 | KDM4E 3022/4885PIK3CD 4599/4885KCNJ1 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.